129 related articles for article (PubMed ID: 8121962)
1. ECT and TRH: cholinergic involvement in a cognitive deficit state.
Khan A; Mirolo MH; Lai H; Claypoole K; Bierut L; Malik R; Bhang J
Psychopharmacol Bull; 1993; 29(3):345-52. PubMed ID: 8121962
[TBL] [Abstract][Full Text] [Related]
2. Effects of low-dose TRH on cognitive deficits in the ECT postictal state.
Khan A; Mirolo MH; Claypoole K; Bhang J; Cox G; Horita A; Tucker G
Am J Psychiatry; 1994 Nov; 151(11):1694-6. PubMed ID: 7943463
[TBL] [Abstract][Full Text] [Related]
3. Opiate antagonism fails to reverse post-ECT cognitive deficits.
Nasrallah HA; Varney N; Coffman JA; Bayless J; Chapman S
J Clin Psychiatry; 1986 Nov; 47(11):555-6. PubMed ID: 3771502
[TBL] [Abstract][Full Text] [Related]
4. Successful use of donepezil in treatment of cognitive impairment caused by maintenance electroconvulsive therapy: a case report.
Rao NP; Palaniyappan P; Chandur J; Venkatasubramanian G; Gangadhar BN
J ECT; 2009 Sep; 25(3):216-8. PubMed ID: 19190508
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological attenuation of electroconvulsive therapy--induced cognitive deficits: theoretical background and clinical findings.
Pigot M; Andrade C; Loo C
J ECT; 2008 Mar; 24(1):57-67. PubMed ID: 18379337
[TBL] [Abstract][Full Text] [Related]
6. Propofol and methohexital as anesthetic agents for electroconvulsive therapy: a randomized, double-blind comparison of electroconvulsive therapy seizure quality, therapeutic efficacy, and cognitive performance.
Geretsegger C; Nickel M; Judendorfer B; Rochowanski E; Novak E; Aichhorn W
J ECT; 2007 Dec; 23(4):239-43. PubMed ID: 18090696
[TBL] [Abstract][Full Text] [Related]
7. Use of thyroid hormone to diminish the cognitive side effects of psychiatric treatment.
Tremont G; Stern RA
Psychopharmacol Bull; 1997; 33(2):273-80. PubMed ID: 9230642
[TBL] [Abstract][Full Text] [Related]
8. Effects of TRH administration on orientation time and recall after ECT.
Zervas IM; Pehlivanidis AA; Papakostas YG; Markianos M; Papadimitriou GN; Stefanis CN
J ECT; 1998 Dec; 14(4):236-40. PubMed ID: 9871843
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological treatment of the cognitive side effects of ECT: a review.
Krueger RB; Sackeim HA; Gamzu ER
Psychopharmacol Bull; 1992; 28(4):409-24. PubMed ID: 1296219
[TBL] [Abstract][Full Text] [Related]
10. Antiepileptic potential and behavioral profile of L-pGlu-(2-propyl)-L-His-L-ProNH2, a newer thyrotropin-releasing hormone analog.
Rajput SK; Krishnamoorthy S; Pawar C; Kaur N; Monga V; Meena CL; Jain R; Sharma SS
Epilepsy Behav; 2009 Jan; 14(1):48-53. PubMed ID: 18952198
[TBL] [Abstract][Full Text] [Related]
11. [Neuropsychologic and clinical effects of protirelin tartrate in patients with stroke sequelae].
Fioravanti M
Ann Ital Med Int; 1990; 5(3 Pt 2):254-61. PubMed ID: 2127687
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic and prophylactic utility of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing electroconvulsive therapy: a randomized controlled trial.
Prakash J; Kotwal A; Prabhu H
J ECT; 2006 Sep; 22(3):163-8. PubMed ID: 16957530
[TBL] [Abstract][Full Text] [Related]
13. S100 and impact of ECT on depression and cognition.
Arts B; Peters M; Ponds R; Honig A; Menheere P; van Os J
J ECT; 2006 Sep; 22(3):206-12. PubMed ID: 16957538
[TBL] [Abstract][Full Text] [Related]
14. Blunted TSH response to TRH and seizure duration in ECT.
Papakostas YG; Markianos M; Pehlivanidis A; Zervas IM; Papadimitriou GN; Stefanis C
Acta Psychiatr Scand; 1999 Jan; 99(1):68-72. PubMed ID: 10066009
[TBL] [Abstract][Full Text] [Related]
15. Strategies to minimize cognitive side effects with ECT: aspects of ECT technique.
Prudic J
J ECT; 2008 Mar; 24(1):46-51. PubMed ID: 18379335
[TBL] [Abstract][Full Text] [Related]
16. Prolactin and TSH responses to TRH and to ECT in pre- and postmenopausal women with major depression.
Markianos M; Lykouras L; Stefanis C
Biol Psychiatry; 1996 Sep; 40(5):403-6. PubMed ID: 8874842
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of cognitive effects during a course of electroconvulsive therapy: recommendations for clinical practice.
Porter RJ; Douglas K; Knight RG
J ECT; 2008 Mar; 24(1):25-34. PubMed ID: 18379332
[TBL] [Abstract][Full Text] [Related]
18. Early effects of electroconvulsive therapy on cognitive function.
Porter R; Heenan H; Reeves J
J ECT; 2008 Mar; 24(1):35-9. PubMed ID: 18379333
[TBL] [Abstract][Full Text] [Related]
19. The impact of galantamine on cognition and mood during electroconvulsive therapy: a pilot study.
Matthews JD; Blais M; Park L; Welch C; Baity M; Murakami J; Sklarsky K; Homberger C; Fava M
J Psychiatr Res; 2008 Jun; 42(7):526-31. PubMed ID: 17681545
[TBL] [Abstract][Full Text] [Related]
20. NS-3 (CG3703), an analog of thyrotropin-releasing hormone, ameliorates cognitive impairment in rats.
Ogasawara T; Ukai Y; Tamura M; Kimura K
Pharmacol Biochem Behav; 1995 Apr; 50(4):499-503. PubMed ID: 7617693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
